Registered Number 07576577

HEAD & NECK CANCER RESEARCH SERVICE

Abbreviated Accounts

31 March 2012

HEAD & NECK CANCER RESEARCH SERVICE

Registered Number 07576577

Balance Sheet as at 31 March 2012

	Notes	2012		
0		£	£	
Current assets Cash at bank and in hand		0.424		
Cash at pank and in hand		9,131		
Total current assets		9,131	-	
Creditors: amounts falling due within one year		(300)		
Net current assets			8,831	
Total assets less current liabilities			8,831	-
Total net Assets (liabilities)			8,831	
Capital and reserves				
Profit and loss account			8,831	_
Shareholders funds			8,831	_

- a. For the year ending 31 March 2012 the company was entitled to exemption under section 477(2) of the Companies Act 2006.
- b. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006
- c. The directors acknowledge their responsibility for:
 - i. ensuring the company keeps accounting records which comply with Section 386; and
 - ii. preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year, and of its profit or loss for the financial year, in accordance with the requirements of section 393, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as is applicable to the company.
- d. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the board on 07 December 2012

And signed on their behalf by:

Dr. Rehan Kazi, Director

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1068 of the Companies Act 2006.

Notes to the abbreviated accounts

For the year ending 31 March 2012

1 Accounting policies

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008).

Turnover

Income represents the grants that the company has received in respect of the research work carried out for the cancer treatment.